uniQure Stock Forecast, Price & News

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure or view top-rated stocks.

Wall Street analysts have given uniQure a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but uniQure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

uniQure is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for uniQure.

uniQure (NASDAQ:QURE) announced its quarterly earnings data on Monday, May, 10th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.89) by $0.02. The biotechnology company earned $0.45 million during the quarter, compared to analysts' expectations of $1.89 million. uniQure had a negative net margin of 366.00% and a negative trailing twelve-month return on equity of 57.38%. The business's quarterly revenue was up 336.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.63) earnings per share.
View uniQure's earnings history.

uniQure's stock was trading at $47.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QURE shares have decreased by 36.7% and is now trading at $30.11.
View which stocks have been most impacted by COVID-19.

16 equities research analysts have issued 1 year target prices for uniQure's shares. Their forecasts range from $40.00 to $100.00. On average, they expect uniQure's stock price to reach $65.40 in the next year. This suggests a possible upside of 117.2% from the stock's current price.
View analysts' price targets for uniQure or view top-rated stocks among Wall Street analysts.

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

Some companies that are related to uniQure include Schrödinger (SDGR), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Legend Biotech (LEGN), Reata Pharmaceuticals (RETA), Apellis Pharmaceuticals (APLS), Allakos (ALLK), Blueprint Medicines (BPMC), HUTCHMED (HCM), Hypera (HYPMY), Galapagos (GLPG), Arena Pharmaceuticals (ARNA), ACADIA Pharmaceuticals (ACAD), Turning Point Therapeutics (TPTX) and Alkermes (ALKS).
View all of QURE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

uniQure trades on the NASDAQ under the ticker symbol "QURE."

uniQure's stock is owned by a variety of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (7.50%), Price T Rowe Associates Inc. MD (4.32%), Point72 Asset Management L.P. (4.15%), BlackRock Inc. (3.19%), Bank of New York Mellon Corp (1.52%) and Artisan Partners Limited Partnership (0.81%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke and Robert Gut.
View institutional ownership trends for uniQure.

QURE stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Federated Hermes Inc., 683 Capital Management LLC, Ameriprise Financial Inc., Renaissance Technologies LLC, Bluefin Capital Management LLC, Millennium Management LLC, and Carlson Capital L P. Company insiders that have sold uniQure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Matthew C Kapusta, and Robert Gut.
View insider buying and selling activity for uniQure or view top insider-selling stocks.

QURE stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Rafferty Asset Management LLC, Citigroup Inc., BlackRock Inc., Hennion & Walsh Asset Management Inc., UBS Group AG, Sivik Global Healthcare LLC, and Geode Capital Management LLC.
View insider buying and selling activity for uniQure or or view top insider-buying stocks.

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QURE stock can currently be purchased for approximately $30.11.

uniQure has a market capitalization of $1.39 billion and generates $37.51 million in revenue each year. The biotechnology company earns $-125,020,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

uniQure employs 332 workers across the globe.

The official website for uniQure is www.uniqure.com.

uniQure is headquartered at PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP.

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]